small-molecule nitroimidazopyran drug candidate treatment tuberculosis
mycobacterium tuberculosis causes tuberculosis greatest single infectious cause mortality worldwide killing roughly two million people annually estimates indicate one-third world population infected latent m tuberculosis synergy tuberculosis aids epidemic- surge multidrug-resistant clinical isolates m tuberculosis reaffirmed tuberculosis primary public health threat however new antitubercular drugs new mechanisms action developed thirty years report series compounds containing nitroimidazopyran nucleus possess antitubercular activity activation mechanism dependent m tuberculosis f420 cofactor nitroimidazopyrans inhibited synthesis protein cell wall lipid contrast current antitubercular drugs nitroimidazopyrans exhibited bactericidal activity replicating static m tuberculosis lead compound pa showed potent bactericidal activity multidrug-resistant m tuberculosis promising oral activity animal infection models conclude nitroimidazopyrans offer practical qualities small molecule potential treatment tuberculosis
